Aktienanalyse zu Xtant Medical Holdings Inc (XTNT)XTNTXtant Medical Holdings Inc

Xtant Medical Holdings, Inc. is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. The Company's products serve the specialized needs of orthopedic and neurological surgeons, as well as trauma, foot and ankle, sports medicine, wound care surgeons including orthobiologics for the promotion of bone healing, amniotic tissue and collagen for both surgical repair and chronic wound care, implants and instrumentation for the treatment of spinal disease. Its orthobiologics products include OsteoSponge, OsteoSelect DBM Putty, OsteoSelect PLUS DBM Putty, 3Demin, OsteoFactor Pro, OsteoVive Plus, and nanOss. Its spinal implant product categories include cervical, thoracolumbar, sacroiliac joint, and interbody. The Company has exclusive United States distribution rights to Dilon's HEMOBLAST Bellows. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Xtant Medical Holdings Inc is a good buy right now due to its recent exclusive partnership with BioHorizons, which is expected to enhance market penetration and revenue. Additionally, the company has raised its 2026 revenue guidance to between $101 million and $105 million, indicating strong growth potential. The current price is $0.28, significantly below the 52-week high of $0.85, suggesting potential for upside. However, the main risk is the negative earnings per share (EPS) of -0.07 reported in the last quarter, which indicates ongoing financial challenges.

2 analysts cover XTNT: 1 rate it Buy, 1 Hold and 0 Sell. The average price target is 1.50.